Michael Hofman, Nuclear Medicine Physician at Peter MacCallum Cancer Centre, shared a post on X:
“The PRINCE trial of Lu-177 PSMA-617 in combination with pembrolizumab has just been published The Lancet Oncology – see first comment for the link.
50% decline in PSA was observed in 76%, with >90% decline in 46%.
There was more toxicity with the addition of immunotherapy including cases of colitis, pancreatitis, pneumonitis, type 1 diabetes, nephritis, myasthenia gravis, optic neuritis and mucosal pemphigus.
I think Lutetium-177 PSMA “combinations” is the future of radioligand therapy, but this combination has significant toxicity. Is there a subset of biologically susceptible cancer where this combination makes sense?
Thanks to Shahneen Sandhu, Peter Mac Cancer Centre, for leading this trial, and all the other investigators across multiple sites including Louise Emmett.”
Title: Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
Authors: Shahneen Sandhu, Anthony M Joshua, Louise Emmett, Mathias Bressel, Angelyn Anton, Lavinia Spain, Lisa G Horvath, Anupama Pasam, Sofie H Tolmeijer, Timothy J Akhurst, Ramin Alipour, Patricia Banks, James P Buteau, Erin Cassidy, Megan Crumbaker, Nattakorn Dhiantravan, Wen Xu, Joanna Chan, Nadia Hitchen, Mark Scalzo, Aravind S Ravi Kumar, Grace Kong, Roslyn Wallace, Narelle Williams, Scott Williams, Nicole M Haynes, Paul Neeson, Alexander W Wyatt, Rodney J Hicks and Michael S Hofman.
Other articles featuring Michael Hofman on OncoDaily.